<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120527009878N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-04-04</date_registration>
      <primary_sponsor>Deputy of Research of Tabriz University</primary_sponsor>
      <public_title>Assessment the efficacy of Tranexamic Acid in reducing blood loss after laminectomy and postrolateral fusion of spine</public_title>
      <acronym></acronym>
      <scientific_title>Assessment the efficacy of Tranexamic Acid in reducing blood loss after laminectomy and postrolateral fusion of spine</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-03-18</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/37109</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The selected patients will be divided into two groups of TXA receptors (n = 25) and placebo recipients (n = 25) according to the random numbers table. All surgical procedures in this study were performed by a surgical team and the technique used was similar.
The randomization in this study is that TXA (15 mg / kg) in single dose and placebo (normal saline 0.09%), which are pre-prepared with the names 1 and 2 in separate syringes, are exactly Prior to cutting by anesthetist technician, an uncontrolled intravenous anesthesia is administered to the patient and the patient is injected randomly, and then an operation is performed on the patient, Blinding description: The selected patients who enter the operating room will be divided into two groups of TXA receptors (n = 25) and placebo recipients (n = 25) according to the random numbers table, which will be informed by the nurse of the operating room. And they will not be aware of it during the operation of the surgical team. All surgical procedures in this study were performed by a surgical team and the technique used was similar. The statistical analyzer is also unaware of the drug method. The basis of the study will be three blinds. After analysis, the head nurse will be asked the type 1 and 2 methods.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Topical administration of TXA helps control bleeding and prevents unwanted side effects.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients between the ages of 20 and 60 who are candidates for laminectomy 2 or more space and fissure with a pedicle screw (CD insertion) for any cause other than trauma at the end of the surgery and before the final fixation and drainage of the trance Topical hexamic acid will be used. Intervention 2: Control group:  Patients aged between 20 and 60 years who are candidates for laminectomy of 2 or more spaces and fistula with a pedicle screw (CD insertion) for any cause other than trauma at the end of the surgery and before the final fixation and embedding Dren will use the drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Moslem Shakeri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht ave</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 44 1333 8507</telephone>
        <email>shakeri@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mansour Valaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht ave</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 44 1333 8507</telephone>
        <email>mvalaie@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with candidate laminectomy and fissure-medial fistula, who refer to Imam Reza Hospital in Tabriz
all patients aged 20 to 60 years</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Use of anticoagulant drugs such as ASA and depiridamole
high PT, PTT, INR for any cause
history of any thrombotic event such as CVA and MI
history of bleeding disorders
history of TBI
history of CPR
kidney failure
OCP use, pregnancy Or lactation.
Also, patients who need blood transfusion before or during surgery for any reason</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M48.06</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Spinal stenosis, lumbar region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients between the ages of 20 and 60 who are candidates for laminectomy 2 or more space and fissure with a pedicle screw (CD insertion) for any cause other than trauma at the end of the surgery and before the final fixation and drainage of the trance Topical hexamic acid will be used.</i_keyword>
      <i_keyword>Control group:  Patients aged between 20 and 60 years who are candidates for laminectomy of 2 or more spaces and fistula with a pedicle screw (CD insertion) for any cause other than trauma at the end of the surgery and before the final fixation and embedding Dren will use the drug.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determination of the Effect of Tranexamic Acid on the Transfusion Level of Blood Transfusion in Patients under Laminectomy and Fibrous Fistula. Timepoint: During surgery and duration of hospitalization after surgery. Method of measurement: Blood volume injected to the patient in milliliters.</prim_outcome>
      <prim_outcome>Determination of the Effect of Tranexamic Acid on the Length of Hospitalization During Laminectomy and Fistula. Timepoint: During surgery and duration of hospitalization after surgery. Method of measurement: Duration of hospitalization in hospital days.</prim_outcome>
      <prim_outcome>Determine the effect of tranexamic acid on the amount of blood collected in hemovac in patients undergoing laminectomy and fissure of the posterolateral of the spine. Timepoint: duration of hospitalization after surgery. Method of measurement: The amount of blood accumulated in CC.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Deputy of Research of Tabriz University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-12</approval_date>
        <contact_name>Ethics Committee of Tabriz Medical science</contact_name>
        <contact_address>Azadi Ave , Golghast St , Imam Reza Hospital Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
